Table 2.

Multivariate analysis of the clinical characteristics prognostic of central nervous system progression

	HR	95% CI	P value
Sex: male vs. female	0.769	0.342–1.729	0.526
Age: ≧70 vs. < 70 years	0.521	0.236–1.150	0.107
ECOG PS: ≧2 vs. < 2	1.013	0.284–3.618	0.984
Brain metastasis: yes vs. no	2.540	1.131–5.702	0.024
EGFR-TKI: erlotinib vs. gefitinib	0.321	0.114–0.903	0.031

In the Cox proportional hazard regression model, the variables adjusted for included sex, age, ECOG PS, presence of brain metastasis at the start of EGFR-TKI treatment, and the EGFR-TKI agent used

ECOG PS Eastern Cooperative Oncology Group performance status, EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor